Non-Opioid EXPAREL Shows Health, Economic Benefits
Pooled data show that EXPAREL® (bupivacaine liposome injectable suspension) slashes opioid consumption, risk of opioid- related side effects, length of postsurgery hospital stay, and cost.
Pooled data show that EXPAREL® (bupivacaine liposome injectable suspension) slashes opioid consumption, risk of opioid- related side effects, length of postsurgery hospital stay, and cost.
Participants experienced an average reduction of 28.1% of subcutaneous fat volume compared with placebo.